Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
XORTX Therapeutics Inc ( (TSE:XRTX) ) has shared an update.
XORTX Therapeutics Inc. announced an upcoming investor webinar and Q&A session, where CEO Dr. Allen Davidoff will discuss the company’s mission and highlight its lead program, XRx-026, for allopurinol-intolerant gout, with an NDA filing expected in the first half of 2026. The announcement underscores XORTX’s strategic positioning in the renal market, with a diversified pipeline and significant market opportunities, including an estimated $700 million per year for XORLO™.
The most recent analyst rating on (TSE:XRTX) stock is a Buy with a C$14.00 price target. To see the full list of analyst forecasts on XORTX Therapeutics Inc stock, see the TSE:XRTX Stock Forecast page.
Spark’s Take on TSE:XRTX Stock
According to Spark, TipRanks’ AI Analyst, TSE:XRTX is a Underperform.
XORTX Therapeutics Inc faces significant challenges with no revenue and consistent losses, leading to a low financial performance score. Technical analysis indicates a neutral to bearish outlook, which, along with poor valuation metrics, weighs down the overall stock score. However, potential advancements in FDA discussions for gout treatment provide a glimmer of hope for future revenue generation, but current financial and compliance risks remain substantial.
To see Spark’s full report on TSE:XRTX stock, click here.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies for gout and progressive kidney disease. The company is advancing products targeting aberrant purine metabolism and xanthine oxidase to decrease uric acid production, with a pipeline that includes treatments for gout, autosomal dominant polycystic kidney disease, acute kidney injury, and diabetic nephropathy.
Average Trading Volume: 4,001
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$4.17M
For an in-depth examination of XRTX stock, go to TipRanks’ Overview page.